Most Read Articles
13 Aug 2019
Individuals with obesity are at an elevated risk of developing infections, particularly that of the skin in both men and women, and those of the gastrointestinal and urinary tracts and sepsis in women only, according to a study.
4 days ago
An increase in intensive care unit (ICU) management and bacterial pneumonia development occurs in children with special risk medical conditions (SRMC), but a rise in the probability of death or need for mechanical ventilation remains inconsistent, suggests a recent study.
Pearl Toh, 30 Aug 2019
Oral amoxicillin–clavulanate effectively promotes resolution of nonsevere acute exacerbations in children with non-cystic fibrosis (CF) bronchiectasis, thus confirming the role of amoxicillin–clavulanate as first-line treatment for bronchiectasis, according to results from the three-arm BEST-1 study.

Original New Drug Application Approvals by US FDA (16 - 31 August 2018)

31 Aug 2018

New drug applications approved by US FDA as of 16-31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

LOPINAVIR; RITONAVIR

  • Active Ingredient(s): Lopinavir; Ritonavir
  • Strength:  unknown
  • Dosage Form: unknown
  • Company: Mylan Labs Ltd
  • Approval Date: August 16, 2018
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Not Applicable
  • Approved Label: Not Applicable
DIACOMIT
  • Active Ingredient(s): Stiripentol
  • Strength: 250 mg; 500 mg
  • Dosage Form: Capsule; oral
  • Company: Biocodex SA
  • Approval Date: August 20, 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
  • Approved Label: 08/20/2018(PDF)
DIACOMIT
  • Active Ingredient(s): Stiripentol
  • Strength: 250 mg; 500 mg
  • Dosage Form: Powder; oral
  • Company: Biocodex SA
  • Approval Date: August 20, 2018
  • Submission Classification:Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
  • Approved Label: 08/20/2018(PDF)
INVELTYS
  • Active Ingredient(s): Loteprednol Etabonate
  • Strength: 1%
  • Dosage Form: Suspension; ophthalmic
  • Company: Kala Pharms Inc
  • Approval Date: August 22, 2018
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for the treatment of post-operative inflammation and pain following ocular surgery.
  • Approved Label: 08/22/2018(PDF)
OXERVATE
  • Active Ingredient(s): Cenegermin-BKBJ
  • Strength: 0.002% (20 mcg/ml)
  • Dosage Form: Solution; ophthalmic
  • Company: Dompe Farmaceutici
  • Approval Date: August 22, 2018
  • Submission Classification: Not Applicable
  • Indication(s): Indicated for the treatment of neurotrophic keratitis.
  • Approved Label: 08/22/2018(PDF)
ALTRENO
  • Active Ingredient(s): Tretinoin
  • Strength: 0.05%
  • Dosage Form: Lotion; topical
  • Company: Dow Pharma
  • Approval Date: August 23, 2018
  • Submission Classification: Not applicable
  • Indication(s): Indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. 
  • Approved Label: 08/23/2018(PDF)
TAKHZYRO
  • Active Ingredient(s): Lanadelumab(SHP643)
  • Strength: 300 mg/ml (150 mg/ml)
  • Dosage Form: Injectable; injection
  • Company: Dyax Corp
  • Approval Date: August 23, 2018
  • Submission Classification: Not applicable
  • Indication(s): Indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older. (1)
  • Approved Label: 08/23/2018(PDF)
XERAVA
  • Active Ingredient(s): Eravacycline
  • Strength: 50 mg
  • Dosage Form: Injectable; injection
  • Company: Tetraphase Pharms Inc
  • Approval Date:  August 27, 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. 
  • Approved Label: 08/27/2018(PDF)
PIFELTRO
  • Active Ingredient(s): Doravirine
  • Strength: 100 mg
  • Dosage Form: Tablet; oral
  • Company: Merck Sharp Dohme
  • Approval Date: August 30, 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated  in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.
  • Approved Label: 08/30/2018(PDF)
DELSTRIGO
  • Active Ingredient(s): Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
  • Strength: 100/300/300 mg
  • Dosage Form: Tablet; oral
  • Company: Merck Sharp Dohme
  • Approval Date: August 30, 2018
  • Submission Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
  • Indication(s): Indicated  as a complete regimen for the treatment of HIV-1 infection in adult patients with no antiretroviral treatment history.  
  • Approved Label: 08/30/2018(PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Aug 2019
Individuals with obesity are at an elevated risk of developing infections, particularly that of the skin in both men and women, and those of the gastrointestinal and urinary tracts and sepsis in women only, according to a study.
4 days ago
An increase in intensive care unit (ICU) management and bacterial pneumonia development occurs in children with special risk medical conditions (SRMC), but a rise in the probability of death or need for mechanical ventilation remains inconsistent, suggests a recent study.
Pearl Toh, 30 Aug 2019
Oral amoxicillin–clavulanate effectively promotes resolution of nonsevere acute exacerbations in children with non-cystic fibrosis (CF) bronchiectasis, thus confirming the role of amoxicillin–clavulanate as first-line treatment for bronchiectasis, according to results from the three-arm BEST-1 study.